title: [The prostate cancer in the community of Madrid in 2000. II Presentation and diagnosis].
abstract: OBJECTIVE
  To know the presentation form, diagnostic method and clinical stage at the time of diagnosis in subjects with prostate cancer (PC) in the Autonomous Community of Madrid in 2000.
  
  
  METHODS
  Data from 1745 patients with histologically confirmed prostate cancer obtained from 15 Hospitals participating in the study was analysed. The variables studied were: associated disease, reason for visiting the hospital, digital rectal examination (DRE), PSA, diagnostic method, graded Gleason score, tests performed in the tumoral extension study and tumour staging. The qualitative variables are given in percentages of the overall number and the quantitative variables are expressed as the median, standard deviation, maximum and minimum values and 25%, 50% (median) and 75% percentiles.
  
  
  RESULTS
  67% cases had an associated disease. In most (75%) patients the reason for visiting the hospital was prostatic syndrome. DRE revealed that 42.7% has no tumour. At the time of diagnosis half the patients had PSA levels lower than or equal to 11 ng/ml. Transrectal ultrasound-guided biopsy was used for diagnosis in 93% subjects. The most commonly reported Gleason scores were 6 (31.3%) and 7 (28.7%). In 75% subjects the disease was considered to be clinically limited to the prostate, in 12.5% locally advanced and in 12.5% metastatic.
  
  
  CONCLUSIONS
  Most patients came to the hospital because of symptoms not related to PC. Transrectal ultrasound-guided biopsy is confirmed as the choice technique for PC diagnosis. When a comparison is made to historical series in our Autonomous Community a pattern of earlier diagnosis can be seen.
authors.affiliation: H.G.U. Gregorio Marañón, Madrid.
authors.forename: F
authors.initials: F
authors.lastname: Herranz Amo
authors.forename: F
authors.initials: F
authors.lastname: Arias Funez
authors.forename: M
authors.initials: M
authors.lastname: Arrizabalaga Moreno
authors.forename: F J
authors.initials: FJ
authors.lastname: Calahorra Fernández
authors.forename: J
authors.initials: J
authors.lastname: Carballido Rodríguez
authors.forename: R
authors.initials: R
authors.lastname: Diz Rodríguez
authors.forename: J A
authors.initials: JA
authors.lastname: Herrero Payo
authors.forename: C
authors.initials: C
authors.lastname: Llorente Abarca
authors.forename: J C
authors.initials: JC
authors.lastname: Martín Martínez
authors.forename: L
authors.initials: L
authors.lastname: Martínez-Piñeiro Lorenzo
authors.forename: R
authors.initials: R
authors.lastname: Mínguez Martínez
authors.forename: J
authors.initials: J
authors.lastname: Moreno Sierra
authors.forename: A
authors.initials: A
authors.lastname: Rodríguez Antolín
authors.forename: J C
authors.initials: JC
authors.lastname: Tamayo Ruiz
authors.forename: J
authors.initials: J
authors.lastname: Turo Antona
mesh_terms: D000328:Adult; D017677:Age Distribution; D000368:Aged; D000369:Aged, 80 and over; D001707:Biopsy, Needle / Q000379:methods; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000379:methods; D008875:Middle Aged; D009367:Neoplasm Staging; D011467:Prostate / Q000000981:diagnostic imaging / Q000473:pathology; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000473:pathology*; D012189:Retrospective Studies; D013030:Spain; D014463:Ultrasonography
chemical_list: D017430:Prostate-Specific Antigen